Navigation Links
Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities
Date:11/3/2008

HAYWARD, Calif., Nov. 3 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover's "Top 10 most interesting projects available for partnering" in their respective categories. MBX-2982, a potential first-in-class treatment for type 2 diabetes, was recognized in the metabolic category and MBX-8025, a potential treatment for a range of dyslipidemias, was recognized in the cardiovascular category. The selections were made by independent committees assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries.

"We are honored to receive this significant recognition for not one, but two of our current programs. This recognition underscores both MBX-2982's potential to become an important new therapy for type 2 diabetes, and MBX-8025's potential in the treatment of dyslipidemia," said Harold Van Wart, Ph.D., Chief Executive Officer of Metabolex.

The metabolic selection committee was led by Marc Wortman, contributing writer to Windhover's IN VIVO and Start-Up, and Harris Kaplan, President & CEO, and Jun Huangpu, Managing Director, of Healogix, a leading business development strategy consulting firm. The cardiovascular selection committee was led by Ed Saltzman, President, and Michael Rice, Senior Consultant, of Defined Health, a leading business development strategy consulting firm.

Drawing on the analytic resources of these organizations, the selection committees evaluated hundreds of compounds currently in development.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive metabolic and cardiovascular
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metabolex Names Zhao, Martin to Executive Posts
2. Metabolex Appoints Donald Hill as Chief Financial Officer
3. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
4. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
5. Maryland Stem Cell Research Commission Recommends 62 Projects for Funding
6. JIC Invests in Three New Alternative Energy Projects
7. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
8. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
9. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be ... cell credentialing course to local area veterinarians. , The tour and course will be ... at no charge) at VetStem’s Poway facility. Staff members are welcome to attend with ...
(Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce ... from the U.S. FDA Center For Biologics Evaluation and ... to conduct a clinical trial investigating the safety and ... female and early male pattern baldness (androgenic alopecia). ... trial, follows initial clinical work in Europe ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/28/2015)... , July 28, 2015 ... company utilizing its proprietary plant-based rhCollagen technology for ... has been appointed Senior Director of Business Development, ... http://photos.prnewswire.com/prnh/20150728/246955 ) , Ms. ... marketing, regulatory and business strategy. Prior to joining ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... ... trainer Dr. Rebecca Fitzgerald, known among her medical colleagues as the "Sculptra guru" here in ... physicians at this year,s 4 day SDEF Cosmetic Dermatology Seminar held in Santa Monica, Ca. ... Los Angeles, Ca ...
... , SANTA ANA, Calif. , ... partnership with Prodimed, a company specializing in women,s health, located ... be distributing Prodimed,s extensive line of embryo transfer catheters, oocyte ... , , Prodimed has a ...
... PALO ALTO, Calif., July 21, Varian, Inc. (NasdaqGS: VARI) plans to ... 2009 after 1:00 p.m. Pacific Time (PT) on Wednesday, July 29, 2009. ... review those quarterly results is scheduled to follow at 2:00 p.m. PT ... webcast can be accessed from Varian, Inc.,s Web site at ...
Cached Biology Technology:Looking Older Than You Are May Have Little to Do With Wrinkles 2Looking Older Than You Are May Have Little to Do With Wrinkles 3
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... Day tomorrow, the popular Newscripts page in Chemical & ... chemistry and romance and hauled in a catch that includes ... pest the bedbug. C&EN is the weekly newsmagazine of ... Newscripts focuses first on a study that checked the authenticity ...
... The University of Manchester is leading the way when it ... ever basic training package to teach students and scientists how ... research. It,s hoped it will encourage more researchers working on ... use the humble fly. The unique scheme has been ...
... new test may help to streamline genetic testing for ... additional testing, and improving turnaround time. The test, which ... methodology, yielded results that were 100% concordant with standard ... high sensitivity and specificity of the test could reduce ...
Cached Biology News:World first for fly research 2World first for fly research 3Novel test streamlines testing for Huntington Disease 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Phospho-FAK (Tyr576/577) Antibody...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Biology Products: